Timothy C. Barabe has served as a member of our Board since January 2022. Mr. Barabe served as the chief financial officer and executive vice president at Affymetrix, Inc. (acquired by Thermo Fisher Scientific Inc.), a provider of life science productions and molecular diagnostic products, from 2010 until his retirement in June 2013. Previously, Mr. Barabe served as senior vice president and chief financial officer of Human Genome Sciences, Inc., a biopharmaceutical company, from July 2006 until March 2010. From 2004 until 2006, he served as chief financial officer of Regent Medical Limited, a U.K.-based, privately owned, surgical supply company, and with Novartis AG, a pharmaceutical company, from 1982 until August 2004 in a succession of senior executive positions in finance and general management, most recently as the chief financial officer of Sandoz GmbH, the generic pharmaceutical subsidiary of Novartis AG. Prior to that, Mr. Barabe served as the president of the Specialty Lens Business Franchise and group vice president and chief financial officer of CIBA Vision Corporation, a contact lenses and lens care product manufacturer until 2003. Mr. Barabe has served on the board of directors of Cartesian Therapeutics, Inc. (NASDAQ: RNAC) since 2016 and previously served on the board of directors of Veeva Systems Inc. (NYSE: VEEV) from September 2015 until June 2021, ArQule, Inc., from 2001 until January 2020, and Opexa Therapeutics, Inc. from 2014 until 2017. Mr. Barabe also currently serves on the board of directors of Vigilant Biosciences, Inc., a private company. Mr. Barabe received a B.B.A. in Finance from University of Massachusetts and an M.B.A. from the University of Chicago. We believe that Mr. Barabe s extensive finance experience, and his service on the board of directors of several other publicly traded companies, qualifies Mr. Barabe to serve on our Board.